CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function

NCT ID: NCT02071602

Last Updated: 2021-03-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-10-31
• Study Completion Date: 2018-11-30

Brief Summary

The primary endpoint is to assess the safety and tolerability of Cenderitide (CD-NP) with the incidence of symptomatic hypotension being one of the key safety variables.

Detailed Description

This is a "proof of concept", randomized, double-blind, placebo controlled study. The study population will include 60 patients admitted with a first time ST elevation anterior STEMI as diagnosed by the following criteria: a) Significant chest discomfort and /or shortness of breath; b) ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial leads; c) Successful reperfusion therapy (>TIMI grade 2 flow) either with thrombolytics or PTCA within 24 hours of onset of symptoms as documented by coronary angiography; and d) No previous history of an anterior AMI or previous ECG suggesting an old anterior AMI.

Patients will be randomized to one of two doses of CD-NP (5 ng/kg/min and 10 ng/kg/min) or placebo continuous infusion for up to 72 hours in a 1:1:1 manner. All patients will receive other standard medical therapies as determined appropriate by the physician and in accordance to the ACC/AHA guidelines

Conditions

ST Elevation (STEMI) Myocardial Infarction of Anterior Wall

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Placebo

Placebo infused for up to 72 hours IV

Group Type: PLACEBO_COMPARATOR

CD-NP

Intervention Type: DRUG

Randomized 1:1:1

CD-NP 5 ng/kg/min

CD-NP 5 ng/kg/min infused for up to 72 hours IV

Group Type: ACTIVE_COMPARATOR

CD-NP

Intervention Type: DRUG

Randomized 1:1:1

CD-NP 10 ng/kg/min

CD-NP 10 ng/kg/min infused for up to 72 hours IV

Group Type: PLACEBO_COMPARATOR

CD-NP

Intervention Type: DRUG

Randomized 1:1:1

Interventions

CD-NP

Randomized 1:1:1

Intervention Type: DRUG

Other Intervention Names

Cenderitide

Eligibility Criteria

Inclusion Criteria

• Significant chest discomfort and /or shortness of breath
• ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial leads
• Successful reperfusion therapy (>TIMI grade 2 flow) either with thrombolytics or any mechanical forms of revascularization, including stent, PTCA, thrombectomy, etc. within 24 hours of onset of symptoms as documented by coronary angiography
• No previously known history of AMI (prior to current cardiac event) or no previous ECG (prior to current cardiac event) suggesting an old AMI (Q wave on presenting ECG is not an exclusion)..

Exclusion Criteria

• Cardiogenic shock, acute heart failure or hypotension (Systolic BP < 90 mmHg)
• Previous known decreased EF < 40%
• Atrial Fibrillation
• Persistent signs and symptoms of Post MI ischemia
• Requirement of pressors for maintenance of blood pressure.
• Intra-aortic blood pump use
• Significant (moderate-severe) valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension.
• Severe congenital heart diseases
• Sustained ventricular tachycardia or ventricular fibrillation
• Second or third degree heart block without a permanent cardiac pacemaker
• Stroke within 3 months or other evidence of significantly compromised CNS perfusion
• Total bilirubin of > 2.5 mg/dL or other liver enzymes >2.5 times the upper limit of normal if available clinically and measured within the last 7 days
• Patients with calculated GFR <30 ml by MDRD equation or those with acute kidney injury as defined by an increase of plasma creatinine of 0.5 mg/dL from a plasma creatinine measured within the last 7 days
• Serum sodium of < 125 mEq/dL or > 160 mEq/dL if available clinically and measured within the last 7 days
• Serum potassium of < 3.0 mEq/dL or > 5.8 mEq/dL if available clinically and measured within the last 7 days
• Hemoglobin < 8.5 gm/dl if available clinically and measured within the last 7 days
• Other acute or chronic medical conditions or laboratory abnormality which may increase the risks associated with study participation or may interfere with interpretation of the data
• Received an investigational drug within 1 month prior to dosing
• Female subject who is pregnant or breastfeeding
• In the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any reasons

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Horng Chen

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Horng Chen, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Countries

United States

Related Links

https://www.mayo.edu/research/clinical-trials

Related Info

Other Identifiers

12-006317

Identifier Type: -

Identifier Source: org_study_id